You just read:

Invivoscribe Submits LeukoStrat® CDx FLT3 Mutation Assay to NMPA in China and Expands Company, Adding Laboratory in Shanghai to Provide Comprehensive Support for Partners

News provided by

Invivoscribe, Inc.

12 May, 2020, 11:00 BST